Cline Scientific

 Excerpt from the CEO's comment in the half-year report:

"The last six months have been a challenging time for our research and development-oriented business, and this is reflected in our financial figures. Happily, our successful issue after the end of the period (during the month of July) has secured the company's finances going forward according to plan. This success shows the trust that our investors have in the company and the hopes that are placed on our projects. We hope to continue to demonstrate our ability to deliver ground-breaking solutions. The resources that we have secured through the issue will be crucial to continue our work in developing innovative products based on our nanotechnology, and now with a primary focus on the StemCART project."

January - June 2023

• Net sales amounted to SEK 0 (0).
• Operating profit amounted to SEK -3,349,005 (-2,554,201
• Earnings per share after tax amounted to SEK -0.17 (-0.17).
• Profit per average number of shares after tax amounted to -0.17 (-0.17)

The report is published at www.clinescientific.com/financial-reports

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8.30am CEST on 25 August 2023.

For more information, please contact:

CEO Hanne Evenbratt, +46 (0)704-887923, hanne.evenbratt@clinescientific.com

Chairman Johan Bjurquist, +46 (0)73-7471990

CFO Håkan Bengtsson, +46 (0)705-558902, hakan.bengtsson@clinescientific.com